Heims & Hers Health Today
Himes and hers health
- 52 week range
- $18.33
▼
$72.98
- P/E ratio
- 61.07
- Price target
- $38.92
shares Hems & Hers Health New York Stock Exchange: HIMSE It was the most important thing in the medical sectorAnd for good reason. The company’s fundamentals are very attractive to investors who prefer to catch growth stories early, before they become too big to be priced for further expansion.
Hims & Hers, with a market capitalization of just $10 billion, is certainly not very big.
The stock is down about 11.4% over the past month, alienating less committed investors. However, this decline also creates an opportunity for dip buyers, as the stock now trades at just 65% of its 52-week high.
This move deep into bearish territory has reignited short seller confidence, pushing short interest near record levels. However, this same setup can provide a great opportunity for contrarian investors.
If the stock regains momentum and begins to rebound, short sellers may be forced to cover their positions — which could trigger a strong short squeeze and fuel a sharp rally in Hims & Hers stock in the coming months.
However, not everything is rosy for the company: part of the recent decline is due to CEO, Andrew Dudom, Selling a block of shareswhich may worry some investors regarding insider confidence.
The CEO’s stock sale was preplanned — not a red flag
This was a scheduled sale for a total value of about $11 million, and was set for August 2024, so it’s not an unexpected or spontaneous event for the company. So, that shouldn’t be a reason for shareholders to worry too much about the CEO.
Perhaps relying on the downward price action and this CEO news, short sellers felt confident enough to raise their stakes, betting against the stock price, which is why interest in the company rose to a high of $4 billion as of September 2025, near an all-time high.
For reference, July 2025 saw the highest level of short interest in Hims & Hers stock at just under $4.3 billion. However, this still represents 31.4% of the stock’s total float, representing high conviction that this CEO event is very bearish.
What investors can take from this is an obvious assumption. However, this could be a defining moment for their portfolios.
If the market is wrong about this scheduled sell-off, there’s a good chance Hims & Hers stock will return to its previous highs, if not break a new ceiling. Investors are now tasked with determining whether this will happen, and there are several ways to do so.
Wall Street sets a bold price target above $60
Hims & Hers Health Stock Forecast Today
$38.92
-20.34% Consreduces
Based on 15 analyst ratings
| Current price | $48.86 |
|---|---|
| High expectations | $68.00 |
| Average expectations | $38.92 |
| Low expectations | $26.00 |
Details of Hims & Hers Health Stock Forecast
All company valuation multiples are based on expected future growth, pushing Hims & Hers’ valuation to 59.3x price-to-earnings (P/E), a significant premium over the medical sector’s current P/E of 29.6x.
Even after the sell-off, markets are still willing to put the company above its peers, and here’s why.
Looking at the company’s quarterly earnings, there are some driving factors that justify what premium markets are paying today. First, revenue growth of 73% year-over-year, which of course carries an industry-leading gross profit margin of 76.2% over the past 12 months.
More than just high revenue growth, it is the company that generates this stream of income. Through subscriptions, Hims & Hers can generate stable and predictable cash flow for management to reinvest in further growth, which is always good news for value maximization and shareholder benefits.
The reported net earnings per share (EPS) figure quantifies this benefit, which came to 17 cents, compared to 6 cents a year earlier. Seeing EPS nearly triple in one year justifies the premium. But this is old news. Investors need to see something ahead in order to feel comfortable about a potential recovery.
While the most immediate catalyst is the market’s identification of why a CEO selloff actually occurred, there is a more quantifiable metric. The latest Wall Street price target is from Maria Reps at Canaccord Genuity Group, who sees the stock rising to $68 per share, roughly 43% above today’s price.
This bold call also stands above the consensus at $38.92, so conviction is not an issue for this analyst. In other news, Hims & Hers reported $19 million in institutional buying over the past quarter, suggesting that the “smart money” is likely to benefit from this pricing error amid CEO selling.
This is far from a risk-free bet, but after falling well below the highs on a shaky bear market basis, Hims & Hers’ risk-reward ratio appears to be one of the best that investors could have carried through the end of 2025.
Before you consider Hims & Hers health, you’ll want to hear this.
MarketBeat tracks the highest-rated and best-performing research analysts on Wall Street and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market goes viral… and Hims & Hers Health was not on the list.
While Hims & Hers Health currently has a low rating among analysts, top-rated analysts believe these 5 stocks are better buys.
View the five stocks here
Enter your email address and we’ll send you a MarketBeat guide to investing in 5G and the 5G stocks that show the most promise.
